{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:01:16Z","timestamp":1778220076229,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jvacx.2020.100074","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T22:07:20Z","timestamp":1597356440000},"page":"100074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9\u201312\u00a0months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Maria Rosario","family":"Capeding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edison","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Feser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susette A.","family":"Audet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy A.","family":"Beeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damon W.","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. William","family":"Letson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Marfin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2020.100074_b0005","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jvacx.2020.100074_b0010","series-title":"Plotkin\u2019s Vaccines","first-page":"511","article-title":"Japanese Encephalitis Vaccines","author":"Halstead","year":"2018"},{"issue":"34","key":"10.1016\/j.jvacx.2020.100074_b0015","first-page":"357","article-title":"Japanese encephalitis: status of surveillance and immunization in Asia and the Western Pacific, 2012","volume":"88","author":"World Health Organization","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jvacx.2020.100074_b0020","unstructured":"UNICEF. Measles Mumps & Rubella: Technical and Supply Information Note; 2015."},{"key":"10.1016\/j.jvacx.2020.100074_b0025","unstructured":"UNICEF. Measles-Containing Vaccines (MCV): Supply & Demand Outlook; 2014."},{"key":"10.1016\/j.jvacx.2020.100074_b0030","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.vaccine.2014.06.036","article-title":"Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14\u201314-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka","volume":"32","author":"Wijesinghe","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0035","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.vaccine.2013.11.002","article-title":"Corrigendum to \u201cComparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14\u201314-2 vaccine in Philippine infants\u201d [Vaccine 26 (2008) 2234\u20132241]","volume":"32","author":"Victor","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0040","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2008.02.042","article-title":"Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14\u201314-2 vaccine in Philippine infants","volume":"26","author":"Gatchalian","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30650-9","article-title":"Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14\u201314\u20132 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial","author":"Li","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jvacx.2020.100074_b0050","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.jvacx.2020.100074_b0055","series-title":"The Immunological Basis for Immunization Series \u2013 Module 7: Measles","year":"2009"},{"key":"10.1016\/j.jvacx.2020.100074_b0060","series-title":"The Immunological Basis for Immunization Series - Module 11: Rubella","year":"2008"},{"key":"10.1016\/j.jvacx.2020.100074_b0065","unstructured":"Mclean H.Q., Hickman C.J., Seward J.F., World Health Organization, Centers for Disease Control and Prevention (\u200e\u200eU.S.)\u200e\u200e. The immunological basis for immunization series - Module 16: Mumps. Geneva: World Health Organization; 2010 https:\/\/apps.who.int\/iris\/handle\/10665\/97885."},{"key":"10.1016\/j.jvacx.2020.100074_b0070","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1016\/j.vaccine.2014.09.012","article-title":"Lot-to-lot consistency of live attenuated SA 14\u201314-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product","volume":"32","author":"Zaman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","article-title":"Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination","volume":"26","author":"Cohen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0080","unstructured":"ZEUS ELISA Mumps IgG Test System [package insert]. Branchburg, NJ. Zeus Scientific; 2014."},{"key":"10.1016\/j.jvacx.2020.100074_b0085","unstructured":"ZEUS ELISA Rubella IgG Test System [package insert]. Branchburg, NJ. Zeus Scientific; 2014."},{"issue":"2","key":"10.1016\/j.jvacx.2020.100074_b0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.99.2.285","article-title":"A plaque reduction test for dengue neutralizing antibodies","volume":"99","author":"Russel","year":"1967","journal-title":"J Immunol"},{"issue":"45","key":"10.1016\/j.jvacx.2020.100074_b0095","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0100","unstructured":"U.S.Department of Health and Human Services Division of AIDS. Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0. http:\/\/rsc.tech-res.com\/Document\/safetyandpharmacovigilance\/DAIDS_AE_GRADING_TABLE_v2_NOV2014.pdf 2014. February 24, 2014."},{"key":"10.1016\/j.jvacx.2020.100074_b0105","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.vaccine.2017.09.026","article-title":"Measles and Rubella Global Strategic Plan 2012\u20132020 midterm review","volume":"36","author":"Orenstein","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0110","first-page":"541","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, October 2019: conclusions and recommendations","volume":"47","author":"World Health Organization","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jvacx.2020.100074_b0120","unstructured":"World Health Organization.: Measles vaccines (position paper). Wkly Epidemiol Rec 2017;92(17):205\u2013228. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255149\/WER9217.pdf?sequence=1."},{"issue":"9","key":"10.1016\/j.jvacx.2020.100074_b0125","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM199003013220903","article-title":"Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines","volume":"322","author":"Markowitz","year":"1990","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jvacx.2020.100074_b0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0033-3506(97)00042-5","article-title":"Effect of vitamin A supplementation on measles vaccination in nine-month-old infants","volume":"111","author":"Semba","year":"1997","journal-title":"Public Health"},{"issue":"36","key":"10.1016\/j.jvacx.2020.100074_b0135","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1016\/j.vaccine.2019.07.049","article-title":"Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: a 10-year follow-up","volume":"37","author":"Carryn","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100074_b0140","series-title":"The Immunological Basis for Immunization Series \u2013 Module 7: Measles","year":"2020"},{"issue":"9","key":"10.1016\/j.jvacx.2020.100074_b0145","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.4161\/hv.29743","article-title":"A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea","volume":"10","author":"Kim","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.jvacx.2020.100074_b0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biologicals.2007.07.002","article-title":"Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines: report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies","volume":"36","author":"Ferguson","year":"2008","journal-title":"Biologicals"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:04:34Z","timestamp":1762913074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136220300218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"alternative-id":["S2590136220300218"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100074","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9\u201312\u00a0months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100074"}}